Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).The analyst commented, "ARCT disclosed additional P2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE